Advanced

Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden

Kaaks, Rudolf; Lundin, Eva; Manjer, Jonas LU ; Rinaldi, Sabina; Biessy, Carine; Soderberg, Stefan; Lenner, Per; Janzon, Lars LU ; Riboli, Elio and Berglund, Göran LU , et al. (2002) In Cancer Causes and Control 13(4). p.307-316
Abstract
Objective: To examine the possible relationships of breast cancer risk to prediagnostic plasma levels of insulin; insulin-like growth factor-I (IGF-I); and IGF-binding proteins -1, -2, and -3. Methods: Within two prospective cohorts in Umea and Malmo we measured plasma concentrations of insulin, IGF-I, and IGFBPs for a total of 513 incident breast cancer cases and 987 matched controls. Results: Globally, risk was unassociated with levels of IGF-I, IGFBP-3, or IGF-I adjusted for IGFBP-3. When breaking down the analysis by subgroups of age at blood donation, an increase in risk was observed for increasing levels of IGF-I in women aged 55 or older, in the Umea cohort only (odds ratios of 1.00, 1.73, 1.76, 1.90; p(trend) = 0.05). This effect... (More)
Objective: To examine the possible relationships of breast cancer risk to prediagnostic plasma levels of insulin; insulin-like growth factor-I (IGF-I); and IGF-binding proteins -1, -2, and -3. Methods: Within two prospective cohorts in Umea and Malmo we measured plasma concentrations of insulin, IGF-I, and IGFBPs for a total of 513 incident breast cancer cases and 987 matched controls. Results: Globally, risk was unassociated with levels of IGF-I, IGFBP-3, or IGF-I adjusted for IGFBP-3. When breaking down the analysis by subgroups of age at blood donation, an increase in risk was observed for increasing levels of IGF-I in women aged 55 or older, in the Umea cohort only (odds ratios of 1.00, 1.73, 1.76, 1.90; p(trend) = 0.05). This effect weakened, however, when the analysis was restricted to subjects who did not use exogenous hormones for the treatment of menopausal symptoms. Levels of IGF-I and IGFBP-3 were not related to risk in younger women, recruited before age 50, contrary to observations from previous studies. In a subcohort where blood samples had been collected after at least four hours of fasting, breast cancer risk showed no clear associations with levels of insulin, IGFBP-1, or IGFBP-2. Conclusions: Our results do not confirm earlier findings of an association of plasma IGF-I levels with breast cancer risk especially in young women, but suggest a possible association with postmenopausal breast cancer risk, possibly among ERT/HRT users only. Our results do not support the hypothesis that elevated plasma insulin levels, and reduced levels of IGFBP-1 and IGFBP-2, are associated with increased breast cancer risk. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
IGFBP-2, IGFBP-1, IGF-I, breast cancer, insulin
in
Cancer Causes and Control
volume
13
issue
4
pages
307 - 316
publisher
Springer
external identifiers
  • pmid:12074500
  • wos:000175276000003
  • scopus:0036001338
ISSN
1573-7225
DOI
10.1023/A:1015270324325
language
English
LU publication?
yes
id
c9593b35-f9f2-4fe6-8777-b8d962ac6eb8 (old id 339646)
date added to LUP
2007-10-31 15:50:12
date last changed
2017-09-17 05:21:53
@article{c9593b35-f9f2-4fe6-8777-b8d962ac6eb8,
  abstract     = {Objective: To examine the possible relationships of breast cancer risk to prediagnostic plasma levels of insulin; insulin-like growth factor-I (IGF-I); and IGF-binding proteins -1, -2, and -3. Methods: Within two prospective cohorts in Umea and Malmo we measured plasma concentrations of insulin, IGF-I, and IGFBPs for a total of 513 incident breast cancer cases and 987 matched controls. Results: Globally, risk was unassociated with levels of IGF-I, IGFBP-3, or IGF-I adjusted for IGFBP-3. When breaking down the analysis by subgroups of age at blood donation, an increase in risk was observed for increasing levels of IGF-I in women aged 55 or older, in the Umea cohort only (odds ratios of 1.00, 1.73, 1.76, 1.90; p(trend) = 0.05). This effect weakened, however, when the analysis was restricted to subjects who did not use exogenous hormones for the treatment of menopausal symptoms. Levels of IGF-I and IGFBP-3 were not related to risk in younger women, recruited before age 50, contrary to observations from previous studies. In a subcohort where blood samples had been collected after at least four hours of fasting, breast cancer risk showed no clear associations with levels of insulin, IGFBP-1, or IGFBP-2. Conclusions: Our results do not confirm earlier findings of an association of plasma IGF-I levels with breast cancer risk especially in young women, but suggest a possible association with postmenopausal breast cancer risk, possibly among ERT/HRT users only. Our results do not support the hypothesis that elevated plasma insulin levels, and reduced levels of IGFBP-1 and IGFBP-2, are associated with increased breast cancer risk.},
  author       = {Kaaks, Rudolf and Lundin, Eva and Manjer, Jonas and Rinaldi, Sabina and Biessy, Carine and Soderberg, Stefan and Lenner, Per and Janzon, Lars and Riboli, Elio and Berglund, Göran and Hallmans, Göran},
  issn         = {1573-7225},
  keyword      = {IGFBP-2,IGFBP-1,IGF-I,breast cancer,insulin},
  language     = {eng},
  number       = {4},
  pages        = {307--316},
  publisher    = {Springer},
  series       = {Cancer Causes and Control},
  title        = {Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden},
  url          = {http://dx.doi.org/10.1023/A:1015270324325},
  volume       = {13},
  year         = {2002},
}